MedTrace Logo

To Evaluate the Efficacy and Safety of Wenxin Keli in Treating Atrial Premature Beats

NCT02319603 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 288

Last updated 2015-07-23

No results posted yet for this study

Summary

A randomized, double-blind, two dose group, parallel-control multi-center, post-marketing clinical trial，to evaluate the efficacy and safety of Wenxin keli in treating atrial premature beats by different dose,to provide a scientific basis for rational clinical use of drug.

Conditions

  • Atrial Premature Beats

Interventions

DRUG

Low dose WenXin keli

Low dose WenXin keli (the original quantity Wenxin keli): specification 10g /bag, Wenxin keli (no sugar) 5 g+ Wenxin keli simulation agent 5g.

DRUG

High dose WenXin keli

High dose WenXin keli(2 times the amount of Wenxin keli): specification 10g /bag, Wenxin keli (no sugar) 10 g.

Sponsors & Collaborators

  • Beijing Bozhiyin T&S Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jihong Guo, doctor · Director of department

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2017-02-28
Completion
2017-02-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02319603 on ClinicalTrials.gov